Orlando Matias, DO
Family Medicine · Okemos, MINPI 1992773402
Payments from drug & device makers
Across 771 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AbbVie$2K
- AstraZeneca$2K
- Pfizer$1K
- Amgen$727
- GSK$635
- plus $4K from 29 others
What the payments were for
- Food & beverage$12,473100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 200 | $2,624 |
| AbbVie(2 entities) | 140 | $2,075 |
| AstraZeneca | 48 | $1,771 |
| Pfizer | 87 | $1,062 |
| Amgen(2 entities) | 59 | $727 |
| GSK | 30 | $635 |
| Abbott | 13 | $456 |
| Boehringer Ingelheim | 21 | $345 |
| Biohaven Pharmaceuticals, Inc. | 19 | $332 |
| Lilly USA, LLC | 19 | $294 |
| Nestle Healthcare Nutrition Inc. | 12 | $255 |
| Merck | 15 | $238 |
| Dexcom, Inc. | 10 | $190 |
| Biohaven Pharmaceutical Holding Company Ltd. | 19 | $152 |
| Sanofi-aventis U.S. LLC | 11 | $150 |
| Exact Sciences | 8 | $135 |
| Lundbeck LLC | 4 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $124 |
| Teva Pharmaceuticals USA, Inc. | 8 | $117 |
| LEO Pharma Inc. | 1 | $107 |
| Mylan Specialty L.p. | 5 | $101 |
| Eisai Inc. | 5 | $83 |
| GRT US Holding, Inc. | 8 | $82 |
| Bayer | 3 | $51 |
| Johnson & Johnson | 3 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Averitas Pharma Inc. | 2 | $35 |
| Impel Pharmaceuticals Inc. | 2 | $30 |
| Medtronic(2 entities) | 2 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| Phadia US Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$546
- AIRSUPRA$321
- FARXIGA$229
- RYBELSUS$226
- BREZTRI$217
- FreeStyle Libre 2$179
- AREXVY$120
- Wegovy$119
- FreeStyle Libre$110
- QULIPTA$109
- UBRELVY$108
- ANZUPGO$107
- ZENPEP$104
- NURTEC ODT$102
How this compares
$12,505 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 54 | $104,900 |
| OzempicSemaglutide | 64 | $88,201 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $50,344 |
| EliquisApixaban | 45 | $49,508 |
| JardianceEmpagliflozin | 40 | $45,624 |
| MounjaroTirzepatide | 20 | $36,595 |
| FarxigaDapagliflozin Propanediol | 25 | $31,341 |
| JanuviaSitagliptin Phosphate | 35 | $29,204 |
| XareltoRivaroxaban | 21 | $20,617 |
| TrulicityDulaglutide | 15 | $17,443 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $14,616 |
| Nurtec OdtRimegepant Sulfate | 13 | $13,350 |
| OxycontinOxycodone Hcl | 13 | $12,944 |
| Spiriva RespimatTiotropium Bromide | 13 | $12,292 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $2,624 | $193,101118 claims |
| PfizerEliquis, Nurtec Odt | $1,062 | $62,85858 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $345 | $57,91653 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $635 | $57,08757 claims |
| Lilly USA, LLCMounjaro, Trulicity | $294 | $54,03935 claims |
| MerckJanuvia, Belsomra | $238 | $33,95146 claims |
| AstraZenecaFarxiga | $1,771 | $31,34125 claims |
| Johnson & JohnsonXarelto | $50 | $20,61721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Okemos
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.